4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.710
-0.130 (-3.39%)
Jun 30, 2025, 4:00 PM - Market closed
4D Molecular Therapeutics Stock Forecast
FDMT's stock price has decreased by -82.32% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts that cover 4D Molecular Therapeutics stock have a consensus rating of "Buy" and an average price target of $32.33, which forecasts a 771.43% increase in the stock price over the next year. The lowest target is $6 and the highest is $44.
Price Target: $32.33 (+771.43%)
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $25 | Strong Buy | Maintains | $28 → $25 | +573.85% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $51 → $44 | Strong Buy | Maintains | $51 → $44 | +1,085.98% | May 9, 2025 |
| Barclays | Barclays | Buy Maintains $45 → $38 | Buy | Maintains | $45 → $38 | +924.26% | May 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +978.17% | Mar 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +654.72% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
4.87M
from 37.00K
Increased by 13,048.65%
Revenue Next Year
4.24M
from 4.87M
Decreased by -12.85%
EPS This Year
-3.63
from -2.98
EPS Next Year
-3.96
from -3.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 21.0M | ||
| Avg | 4.9M | 4.2M | 4.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56,656.8% | 331.7% | 395.3% | ||
| Avg | 13,048.6% | -12.8% | -5.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.22 | -2.94 | -1.64 | ||
| Avg | -3.63 | -3.96 | -4.02 | ||
| Low | -3.98 | -5.04 | -6.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.